302 related articles for article (PubMed ID: 34978890)
1. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
[TBL] [Abstract][Full Text] [Related]
2. Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6.
Hu Z; Cordwell T; Nguyen H; Li J; Jeffrey JL; Kuritzkes DR
J Infect Dis; 2023 Nov; 228(10):1352-1356. PubMed ID: 37497681
[TBL] [Abstract][Full Text] [Related]
3. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
Scheibe K; Urbańska A; Serwin K; Parczewski M
Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
[TBL] [Abstract][Full Text] [Related]
5. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
6. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
7. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions.
Rusconi S; Santoro MM; Capetti AF; Gianotti N; Zazzi M
Int J Antimicrob Agents; 2022 Sep; 60(3):106627. PubMed ID: 35760225
[TBL] [Abstract][Full Text] [Related]
8. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
[TBL] [Abstract][Full Text] [Related]
9. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
[TBL] [Abstract][Full Text] [Related]
11. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
12. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
[TBL] [Abstract][Full Text] [Related]
13. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Cutrell AG; Schapiro JM; Perno CF; Kuritzkes DR; Quercia R; Patel P; Polli JW; Dorey D; Wang Y; Wu S; Van Eygen V; Crauwels H; Ford SL; Baker M; Talarico CL; Clair MS; Jeffrey J; White CT; Vanveggel S; Vandermeulen K; Margolis DA; Aboud M; Spreen WR; van Lunzen J
AIDS; 2021 Jul; 35(9):1333-1342. PubMed ID: 33730748
[TBL] [Abstract][Full Text] [Related]
14. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
[TBL] [Abstract][Full Text] [Related]
15. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
[TBL] [Abstract][Full Text] [Related]
16. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Orkin C; Schapiro JM; Perno CF; Kuritzkes DR; Patel P; DeMoor R; Dorey D; Wang Y; Han K; Van Eygen V; Crauwels H; Ford SL; Latham CL; St Clair M; Polli JW; Vanveggel S; Vandermeulen K; D'Amico R; Garges HP; Zolopa A; Spreen WR; van Wyk J; Cutrell AG
Clin Infect Dis; 2023 Nov; 77(10):1423-1431. PubMed ID: 37340869
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
Chounta V; Snedecor SJ; Wu S; Van de Velde N
BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
[TBL] [Abstract][Full Text] [Related]
19. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
20. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
Blackwell CW; López Castillo H
J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
